Not yet recruiting
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· Phase 3· CSL Behring· Source
Contact: Trial Registration Coordinator
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
NCT07831902· Phase 3· University College, London· Source
Contact: Anupama Gore (principal investigator)
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Not yet recruiting
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
NCT07602946· Phase 2· University of Southampton· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801· Phase 2· Hoffmann-La Roche· Source
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Contact: Harriet Walker, Dr
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source
Contact: Harriet Walter, MD
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Sean Dulloo, Site 0033
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598· Phase 2· Hoffmann-La Roche· Source
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013· Phase 1/2· Eli Lilly and Company· Source
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172· Phase 1· Epkin· Source
Contact: Epkin
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Samreen Ahmed, Site 0026
Recruiting
Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery
NCT04103372· Imperial College London· Source
Contact: Principal Investigator
Recruiting
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
NCT05990192· Phase 2· Institute of Cancer Research, United Kingdom· Source
Contact: Donna Ward
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Recruiting
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
NCT05655078· University College, London· Source
Contact: Thiagarajan Sridhar
Active, not recruiting
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738· Phase 1· Boehringer Ingelheim· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Boehringer Ingelheim· Source
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665· Phase 1· Genentech, Inc.· Source
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Cancer Research UK· Source
Contact: Harriet Walter, Dr
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Cancer Research UK· Source
Contact: Olubukola Ayodele, Dr
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085· Phase 3· Celgene· Source
Contact: Shelina Sachedina, Site 0131
Active, not recruiting
CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)
NCT04678869· University College, London· Source
Recruiting
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05085028· Phase 3· Imperial College London· Source
Contact: Samreen Ahmed
Recruiting
Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
NCT05604963· University College, London· Source
Contact: Oladejo Olaleye (principal investigator)
Active, not recruiting
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
NCT04546620· Phase 2· University Hospital Southampton NHS Foundation Trust· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350· AgNovos Healthcare, LLC· Source
Contact: RESTORE Study
Recruiting
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT04663750· Phase 3· King's College Hospital NHS Trust· Source
Contact: Somnath Banerjee (principal investigator)
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242· Phase 3· Pfizer· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Contact: Emma Ross
Active, not recruiting
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
NCT04217278· Phase 2/3· University of Birmingham· Source
Recruiting
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502· Phase 3· University of Birmingham· Source
Contact: Natalia Morelli
Showing 50 of 61.